Immunity Project
-99%
est. 2Y upside i
The free HIV vaccine.
Rank
#4387
Sector
Biotechnology
Est. Liquidity
~5Y
Data Quality
Data: LowThis opportunity is primarily mission-driven; the 'equity' in a non-profit Immunity Project is highly unlikely to provide significant financial returns or liquidity, and the lack of recent progress combined with low funding makes it an extremely high-risk proposition for financial upside.
Last updated: February 16, 2026
Immunity Project secures substantial new philanthropic funding, achieves a major scientific breakthrough in HIV vaccine development, and successfully progresses into advanced clinical trials, leading to a modest, pre-defined financial incentive payout for 'equity' holders.
The project continues to operate with limited funding and slow progress, or the 'equity' remains nominal with no clear path to financial realization within the two-year horizon, reflecting the inherent limitations of a non-profit structure.
The project stalls due to insufficient funding, clinical trial failures, or overwhelming competitive pressure, resulting in the complete loss of any perceived financial value of the 'equity' within the non-profit framework.
Community
Valuation Sentiment
Our model estimates -99% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.